WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
The 22nd China International Environmental Protection Exhibition was held in BeijingScenery of Xiezi Mountain in China's ShandongPeng Liyuan Meets Brazilian First LadyWorld Insights: Xi's Russia Visit Deepens Bilateral Cooperation, Contributes to Human ProgressPeople go outside to enjoy scenery of flowers in many parts of ChinaSnow scenery of Xuexiang National Forest Park in HeilongjiangCity view of China's Chongqing MunicipalityVillage benefits from ecological improvement of Erhai Lake in YunnanGiant panda activities frequently captured at a nature reserve in SW ChinaXi's Article on New Development Pattern to Be Published